Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Phenylketonuria
Interventions
DRUG

SYNB1618

15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618

DRUG

SYNB1934

15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934

Trial Locations (11)

10029

Icahn School of Medicine at Mount Sinai, New York

15224

University of Pittsburgh Medical Center, Pittsburgh

32608

University of Florida College of Medicine, Gainesville

33434

Excel Medical Clinical Trials, LLC, Boca Raton

37232

Vanderbilt University Medical Center, Nashville

63110

Washington University in St Louis, St Louis

77030

University of Texas Health Science Center at Houston, Houston

80045

Children's Hospital Colorado, Aurora

84124

PRA Health Sciences, Salt Lake City

84132

University Hospital Adult Services, Salt Lake City

97201

Oregon Health and Science University, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Synlogic

INDUSTRY

NCT04534842 - Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria | Biotech Hunter | Biotech Hunter